DaVita Inc. announced that it has entered into a six year supply agreement with Amgen, replacing prior agreements that were to expire in 2018.  This agreement continues DaVita's long-term relationship with Amgen focused on serving kidney care patients. The agreement, among other things, provides for discount pricing and rebates for Epogen and Aranesp. Through this agreement DaVita has committed to purchase Epogen and Aranesp in amounts necessary to meet a minimum percentage of the company's and its affiliates' requirements for erythropoiesis stimulating agents in the United States. While the percentage varies during the term of the agreement, in no year will it be less than 90% of ESA requirements.